Ben has worked on matters relating to both small molecule and antibody drugs for a variety of life sciences clients. He has a particular interest in the chemical and life sciences sectors due to his background in chemistry. Prior to joining Bristows, Ben completed a masters in organic chemistry and published his work on transition-metal-free synthetic methodology in Angewandte Chemie International.

Ben works on pre-litigation strategic issues, coordination of multi-jurisdiction patent litigation as well as active litigation before the courts in the UK. As part of this work, Ben has engaged a wide range of technical experts.

Ben’s work highlights include:

• Celltrion v Genentech & Novartis – litigation in the High Court relating to XOLAIR (omalizumab) formulation.

Prior to joining Bristows in 2023, Ben completed his training contract with a magic circle law firm.